AnaptysBio (NASDAQ: ANAB)
AnaptysBio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
AnaptysBio Company Info
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
News & Analysis
Why AnaptysBio Was Such a Healthy Stock This Week
The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
A powerfully bullish new analyst take on the company helped it rally on the market.
Why AnaptysBio Stock Is Popping Today
This analyst is excited about the company's prospects.
Why AnaptysBio Plummeted Today
The company's leading drug candidate failed to meet its primary endpoint in a phase 2 clinical trial.
Why AnaptysBio Was a Stock Market Star on Friday
There was some encouraging news from across the Atlantic.
Why AnaptysBio Fell by as Much as 10% Today
Perhaps no news is bad news for the ambitious biotech.
Why AnaptysBio Trounced the Market on Thursday
The biotech got a sharp upward shift in recommendation and target price from a prominent analyst.
Here's Why AnaptysBio Rose 22.1% in May
The beaten-up biopharma provided an update that revved up interest in its pipeline.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.